In an unprecedented and comprehensive study published in Nature Genetics, researchers at St. Jude Children’s Research Hospital, alongside collaborators worldwide, have unveiled groundbreaking insights into the genetic mechanisms that allow blood stem cells to evade immune destruction in aplastic anemia. This life-threatening disorder, marked by the failure of the bone marrow to produce sufficient blood cells, has long puzzled scientists studying its transition to more severe diseases like myelodysplastic syndrome (MDS) and leukemia. The new findings reveal that blood stem cells within the same individual independently acquire multiple distinct genetic mutations to escape the autoimmune attack, fundamentally reshaping our understanding of this disease’s biology and its implications for patient treatment and prognosis.
Aplastic anemia arises as autoreactive T cells mistakenly target hematopoietic stem and progenitor cells due to recognition of peptides presented by specific human leukocyte antigen (HLA) molecules. Each individual inherits two copies of the HLA gene, and certain “risk” alleles of this gene are implicated in inducing immune-mediated destruction of these vital blood-forming cells. Crucially, the study demonstrates that hematopoietic stem cells circumvent this autoimmune challenge by silencing the expression of the risk-bearing HLA alleles, either through loss-of-function mutations or uniparental isodisomy of chromosome arm 6p (UPD6p), which replaces the risk allele with a non-risk version. This immune escape mechanism was not fully understood before, especially regarding whether these genetic changes occur sequentially within a clone or independently across multiple stem cells.
Employing cutting-edge single-cell DNA sequencing technologies, the research team profiled over 300,000 individual cells to decode the mutational landscape and surface protein expression patterns. They uncovered that in patients who escape immune destruction, multiple independent clones harbor protective mutations and proliferate concurrently rather than arising from a singular ancestral clone. This phenomenon of convergent evolution within the bone marrow reveals an extraordinary adaptive process whereby distinct hematopoietic stem cells independently acquire mutations that confer immune evasion. These clones successfully repopulate the marrow, escaping the autoimmune onslaught and allowing blood production to resume—a finding that challenges the previous assumption that such mutations might predispose to malignant transformation.
The presence of these immune-evading clones correlates with improved clinical outcomes, including the restoration of normal blood counts and extended remission periods in aplastic anemia patients. Contrary to earlier concerns, the study indicates these protective clones bear a benign profile without increased risks of progression to MDS or leukemia. This challenges fundamental notions about the relationship between clonal hematopoiesis and oncogenesis in this setting. Notably, the data reveal that clones with silenced risk HLA alleles rarely coexist with those bearing mutations commonly found in clonal hematopoiesis of indeterminate potential (CHIP), suggesting that HLA loss alone provides sufficient proliferative advantage, possibly suppressing the selective pressure for oncogenic mutations.
The investigation encompassed a cohort of 619 aplastic anemia patients, including 256 children and 363 adults, representing the largest pediatric cohort examined to date. They observed that acquired mutations associated with immune evasion were equally prevalent in both adults and children. Interestingly, pediatric patients exhibited CHIP mutations largely confined to fewer genes—BCOR, BCORL1, and ASXL1—that are not typically associated with age-related changes, implying that these mutations are specifically acquired as a response to immune pressures rather than aging. This distinction underscores the dynamic nature of hematopoietic adaptation in young patients and illustrates how immune escape can drive mutagenesis independent of chronological aging.
Whole-genome sequencing at the single-cell level allowed the team to reconstruct phylogenetic lineages, tracing the origins and timing of these mutational events. Instead of emerging immediately before disease onset, many protective HLA-loss clones originated years prior to clinical diagnosis, illustrating a prolonged, covert evolutionary process occurring early in life. This insight redefines the temporal landscape of aplastic anemia pathogenesis and suggests that immune-driven selective pressures shape hematopoiesis long before symptoms manifest.
The discovery of elevated CD34 expression on long-lived rescued clones offers a potential biomarker for monitoring marrow recovery, as CD34 marks hematopoietic stem and progenitor cells capable of sustained growth and differentiation. This finding could translate into clinical applications by refining prognostic assessments and guiding therapeutic decisions aimed at harnessing or augmenting these protective clones to improve patient outcomes.
Remarkably, the study delineates that HLA risk allele loss and CHIP mutations act as mutually exclusive escape pathways within individual cells. The lack of co-occurrence suggests a protective rather than oncogenic function of HLA loss mutations, which not only assist in immune evasion but potentially guard against malignant transformation. This paradigm shift elucidates how the hematopoietic system employs independent, parallel evolutionary strategies to counteract autoimmunity without escalating cancer risk.
Marcin Wlodarski, MD, PhD, the study’s corresponding author, emphasizes that aplastic anemia manifests as a “miniature model of convergent evolution,” where multiple, independent mutational events converge functionally to silence autoimmunity. Such an intrinsic ability of human hematopoiesis to self-correct and restore healthy blood formation offers novel avenues for therapeutic innovation. Understanding these mutational dynamics may inspire novel treatments that promote selective expansion of protective clones or guide immune modulation strategies to prevent recurrent attacks.
Supported by a constellation of grants from organizations spanning the National Institutes of Health to the American Society of Hematology and international foundations, this work exemplifies collaborative efforts bridging clinical hematology, genomics, and evolutionary biology. It leverages state-of-the-art technologies including long-read sequencing and single-cell multi-omic approaches, setting new standards for disease modeling and precision medicine in blood disorders.
These revelations carry profound implications beyond aplastic anemia, shedding light on fundamental principles of hematopoietic plasticity and immune escape that may translate to other autoimmune or bone marrow failure syndromes. They underscore the intricate balance between genetic diversity, immune selection, and clonal evolution that governs human blood cell development and disease.
In summary, this landmark study overturns previous dogma by demonstrating that protection from immune-mediated marrow failure arises via multiple, distinct clones independently acquiring mutations that silence the deleterious HLA risk alleles. These clones foster durable remission and do not portend malignant progression, highlighting an extraordinary natural reparative mechanism intrinsic to human hematopoiesis. The work paves the way for leveraging genetic and cellular biomarkers to forecast clinical outcomes and design targeted therapies, heralding a new era in the management of aplastic anemia and related disorders.
Subject of Research: Blood stem cell genetics and immune evasion in aplastic anemia
Article Title: Blood stem cells evade immunity in aplastic anemia by similar genetic mutations arising independently
News Publication Date: May 1, 2026
Web References:
https://www.stjude.org/
http://dx.doi.org/10.1038/s41588-026-02587-x
Image Credits: St. Jude Children’s Research Hospital
Keywords: Aplastic anemia, immunity, blood stem cells, clonal hematopoiesis, HLA mutations, immune evasion, bone marrow failure, convergent evolution, pediatric hematology, myelodysplastic syndrome, leukemia risk, single-cell genomics
